Skip to main content

Affymetrix Q1 Revenues Jump, Net Loss Narrows

NEW YORK, April 21 (GenomeWeb News) - Affymetrix today reported an increase in revenues and a dramatic narrowing of its net loss compared to the year ago quarter.


The market leader in the mass production of microarrays, Affymetrix reported total revenues of $79 million for the quarter that ended March 31, compared to total revenues of $67 million for the year-ago quarter.


The company had a net loss of $1.9 million for the quarter, compared to a loss of $12.7 million for its first quarter of 2003. The loss included a charge of $8.1 million associated with the company's redemption of a set of 4.75 and 5.0 percent convertible subordinated notes.


The company reported research and development expenses of $17 million, compared to $16 million for the same quarter in 2003.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.